All articles tagged with #alzheimers
In a mid-stage Phase 2 trial, Biogen's experimental Alzheimer’s drug diranersen slowed cognitive decline to rates similar to approved therapies and reduced brain tau, a result that supports advancing to Phase 3 pending confirmation.
At AAIC, researchers highlighted a Latin American study hailed as landmark showing that an intensive, structured risk-reduction program—focusing on diet, exercise, cardiovascular monitoring, and social engagement—better preserved cognitive function in older adults at risk for dementia than a less structured approach, underscoring that healthy habits support brain health.
Memory loss isn’t always the first sign of early-onset Alzheimer’s; many patients first show executive-function, language, vision, or personality changes, which can delay diagnosis. Most cases before 65 aren’t genetic, though about 5% involve gene mutations; roughly 360,000 Americans are affected. Advances in biomarkers—amyloid and tau PET scans, spinal fluid tests, and increasingly blood tests like p-tau217—now allow diagnosis in living patients and could democratize access. Clinicians use detailed histories, MRI, and biomarker results to diagnose and discuss treatments, including monoclonal antibodies targeting amyloid and emerging tau therapies, moving toward biology-based classification and personalized, combination therapies. The LEADS study aids early-onset diagnosis and trial access, underscoring a shift to earlier, biology-driven care for younger patients.
King's College London researchers identify karyoptosis, a nucleus-destructing process triggered by waste buildup in neurons, as a significant contributor to brain cell death in Alzheimer's and frontotemporal dementia. The enzyme p38 MAP kinase marks LaminB1 for destruction, causing nuclei to disintegrate; blocking this interaction delayed cell death in experiments, suggesting a potential therapeutic route. Analysis of human and animal brain cells showed higher rates of karyoptosis in dementia patients (about 35% of frontal-cortex cells) than in healthy controls (about 15%). The study, published in Nature Communications, points to new targets to slow neuron loss and extend treatment windows.
A Swedish study of over 1,800 people aged 60+ followed for up to 15 years found that diets with lower inflammatory potential—rich in vegetables, fruits, nuts, legumes and whole grains and lower in ultraprocessed foods, sugary drinks and red meat—were linked to a reduced dementia risk, including among participants with higher Alzheimer’s biomarkers like p-tau217. While observational and not proof of causation, the findings support a broader brain-health pattern: pair a whole, minimally processed diet with lifestyle factors like physical activity and vascular health, leaning toward Mediterranean-style eating for potential cognitive benefits.
A two-year, randomized trial in 365 older adults at elevated Alzheimer’s risk found that 2,000 mg/day DHA reaches the brain but does not improve memory or slow brain atrophy versus placebo, even among APOE ε4 carriers. Potential reasons include DHA metabolism in the brain and inflammation from cardiovascular risk factors; the relatively young, lightly affected cohort and high dropout limit generalizability. The study reinforces that lifestyle factors (regular exercise, sufficient sleep, and a balanced diet) remain the best available dementia risk-reduction strategy while future work explores DHA metabolism, biomarkers, and personalized approaches.
Researchers at the University of Utah report that Arc, a brain protein important for neuron signaling, also helps package and transmit the toxic tau protein between brain cells in Alzheimer’s models. In mice lacking Arc, neuron-to-neuron tau transmission dropped significantly, suggesting Arc could be a new target to slow disease progression. However, Arc is also vital for learning and memory, so therapies would need to block tau transport without disrupting Arc’s normal function. Most findings come from mouse studies, and it remains unclear how well this translates to humans.
A Springer Nature study found that elevated blood levels of the biomarker pTau181 in 45-year-olds are linked to self-reported cognitive concerns, suggesting signals of dementia risk may begin in midlife even when standard cognitive tests and brain scans are normal. This could indicate an early window for prevention, but it does not prove future dementia. In the UK, about 1 in 11 people aged 65+ have dementia, with risk roughly doubling every five years after around 70.
A viral TikTok claim that wiggling the pinky daily can prevent Alzheimer's is unsupported; while finger-tapping tasks show how movement and attention relate to aging, they are not diagnostic tools or proven defenses against dementia. Real brain health comes from broader lifestyle factors—regular exercise, good sleep, Mediterranean-style diet, social engagement, treating hearing and vision issues, and lifelong learning—while single tricks are unlikely to provide lasting protection.
New findings from the Framingham Heart Study show that loss of slow-wave (deep) sleep in people over 60 is associated with a higher risk of dementia—each 1% yearly decrease in slow-wave sleep links to a 27% higher dementia risk, rising to 32% for Alzheimer's. Slow-wave sleep declines with age and supports brain clearance of waste, but causality isn’t proven; more research is needed. In the meantime, prioritizing sleep and strategies to boost deep sleep may be beneficial.
Emma Heming Willis has clarified that Bruce Willis's dementia is frontotemporal dementia (FTD), not Alzheimer's, noting he was diagnosed with aphasia in 2022 and with FTD in 2023; she explains FTD affects behavior and language and that he still recognizes family, while describing his care setup at a single-storey home with a full-time team and pushing back against online criticism of caregivers.
Scientists identify the enzyme GRK2, and its inactive form, as a new target in Alzheimer's disease. In mouse models and some human brain tissue, inactive GRK2 accumulates with mitochondria, boosting amyloid-beta production and harming mitochondrial function. The compound dubbed Compound 10 prevents GRK2 from clumping, restoring mitochondrial health, reducing amyloid-beta, and slowing dementia progression in mice, marking a potential new therapeutic avenue that still needs validation in humans.
ETH Zurich researchers identify inactive GRK2 aggregates that disrupt mitochondrial energy and drive amyloid beta buildup in Alzheimer’s, forming a damaging feedback loop. They developed Compound 10, which blocks GRK2 aggregation, preserves mitochondrial function, reduces amyloid beta, and slows nerve-cell loss in mice, suggesting a new upstream therapeutic approach that could complement existing treatments; a patent has been filed and industry partnerships are being pursued.
An 80-year-old woman with long-standing Alzheimer’s who had barely spoken for years began talking 19 hours after a high-dose psilocybin session, with autobiographical memory, humor, and motor function returning for weeks. The case, published as a study, suggests potential for psychedelics in treating Alzheimer’s but is limited by being a single case and not a cure, warranting further research.
A review published in Science argues that sleep drives a brain-cleaning process via the glymphatic system that clears waste such as amyloid-beta and tau. This flow is coordinated by shifts in neuromodulators and heart-rate variability, potentially detectable with smartwatches, and could signal brain health risks. The work reinforces sleep as essential for preventing dementia, though more human studies are needed to confirm how sleep disruption contributes to disease and to explore future therapies.